Mortality risk increased with worse glycemic control among patients who had had diabetes for less than five years, while a mean HbA1c level between 6.5% to 7.9% was associated with the lowest mortality risk in those who had had the disease longer.
Patients with type 1 diabetes who were randomly assigned to insulin treatment with a closed-loop system spent more time in the target glycemic range than those assigned to a sensor-augmented pump.
Adding weight management to group visits didn't change HbA1c, but improved weight loss, hypoglycemia
Incorporating intensive weight management with a low-carb diet into standard group medical visits for patients with diabetes “should be considered as an alternative, noninferior approach for glycemic management that has additional clinical advantages,” study authors concluded.
Recent research quantified vertebral fractures in patients with type 2 diabetes, compared fracture risks of starting sodium-glucose cotransporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors, and measured bone mineral density in patients with type 1 diabetes.
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD
Baseline kidney disease, albuminuria, and cardiovascular disease (CVD) status may help determine which patients will benefit most from sodium-glucose cotransporter-2 inhibitors, according to an ACP Journal Club commentary.